Q&A Session with Biosimilar Roundtable Panelists – Dr Marius Schmid

Dr. Marius Schmid headshot
Zentriforce logo

Dr. Marius Schmid

Dr. Marius Schmid is highly experienced in all aspects of biophysical analysis, previously as a senior scientist and Head of Analytical Ultracentrifugation (AUC) and AF4 at Coriolis Pharma. In 2019, he co-founded and became CEO of the Heidelberg-based Zentriforce Pharma Research GmbH, a CRO specializing in hydrodynamic analysis techniques for biopharmaceuticals and gene therapy products.

FG: Marius, what was the stimulus that made you set up Zentriforce? Do you believe that both biopharma CMC experts and regulators are now more aware of the benefits of techniques to probe higher order structure?

af4 instrument

FG: And, in your experience, do you believe that both biopharma CMC experts and regulators are now more aware of the benefits of techniques to probe higher order structure?

FG: What then are the main challenges your hydrodynamic methods face when you perform comparative biosimilar analyses?

FG: Apart from Biosimilars, you mentioned that you are heavily involved with the analysis of AAVs for Gene Therapy products. Are the approaches you take to these different classes of molecules the same or different?

aav analysis